AGEN
Agenus Inc.
Price Chart
Latest Quote
$2.86
Current Price| Previous Close | $2.84 |
| Open | $2.85 |
| Day High | $2.97 |
| Day Low | $2.80 |
| Volume | 502,810 |
Stock Information
| Shares Outstanding | 36.14M |
| Total Debt | $46.15M |
| Cash Equivalents | $3.46M |
| Revenue | $106.83M |
| Net Income | $-35.38M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $103.37M |
| EPS (TTM) | $-1.57 |
| Exchange | NCM |
📊 Custom Metrics & Score
Score: 18/42| Debt to Equity | -0.29 |
| Debt to Earnings | -1.81 |
| Current Ratio | 0.21 |
| Quick Ratio | 0.18 |
| Avg Revenue Growth | -16.25% |
| Profit Margin | -219.61% |
| Return on Equity | 69.62% |
| Avg FCF Growth | 142.83% |
| FCF Yield | -153.72% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $2.86 | 502,810 |
| 2026-01-30 | $2.84 | 519,200 |
| 2026-01-29 | $2.99 | 805,300 |
| 2026-01-28 | $3.11 | 373,300 |
| 2026-01-27 | $3.19 | 509,900 |
| 2026-01-26 | $3.02 | 1,189,700 |
| 2026-01-23 | $3.24 | 476,300 |
| 2026-01-22 | $3.38 | 460,600 |
| 2026-01-21 | $3.40 | 889,100 |
| 2026-01-20 | $3.37 | 851,300 |
| 2026-01-16 | $3.34 | 1,738,900 |
| 2026-01-15 | $3.68 | 3,180,000 |
| 2026-01-14 | $4.68 | 1,242,200 |
| 2026-01-13 | $4.61 | 1,452,900 |
| 2026-01-12 | $4.25 | 941,600 |
| 2026-01-09 | $3.91 | 685,800 |
| 2026-01-08 | $3.75 | 666,400 |
| 2026-01-07 | $3.70 | 955,200 |
| 2026-01-06 | $3.47 | 907,200 |
| 2026-01-05 | $3.22 | 278,700 |
About Agenus Inc.
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
📰 Latest News
Agenus Webcast: Zydus Manufacturing Deal Closes, France Access Expands, Phase 3 BATMAN Nears Launch
MarketBeat • 2026-01-29T01:00:08Z
Agenus (AGEN) Q2 2025 Earnings Call Transcript
Motley Fool • 2026-01-27T16:43:55Z
Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal
Hospital Management • 2026-01-16T10:08:10Z
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?
Zacks • 2026-01-13T17:00:04Z
Agenus (AGEN) Q3 2024 Earnings Call Transcript
Motley Fool • 2026-01-05T23:24:30Z
Agenus (AGEN) Q4 2024 Earnings Call Transcript
Motley Fool • 2026-01-05T21:52:00Z
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates
Zacks • 2025-11-10T13:40:02Z
Agenus: Q3 Earnings Snapshot
Associated Press Finance • 2025-11-10T12:37:46ZIntellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates
Zacks • 2025-11-06T22:20:03Z
Innoviva (INVA) Q3 Earnings and Revenues Beat Estimates
Zacks • 2025-11-05T23:40:02Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $156,014,000 | $237,680,000 | $197,259,000 | $182,078,000 |
| Cost Of Revenue | $156,014,000 | $237,680,000 | $197,259,000 | $182,078,000 |
| Total Revenue | $103,463,000 | $156,314,000 | $98,024,000 | $295,665,000 |
| Operating Revenue | $2,485,000 | $41,742,000 | $52,739,000 | $251,126,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $117,626,000 | $97,925,000 | $61,863,000 | $65,719,000 |
| Total Expenses | $227,892,000 | $316,419,000 | $278,266,000 | $258,437,000 |
| Other Income Expense | $9,784,000 | $593,000 | $11,449,000 | $-233,000 |
| Other Non Operating Income Expenses | $5,830,000 | $37,000 | $12,571,000 | $5,051,000 |
| Net Non Operating Interest Income Expense | $-117,626,000 | $-97,925,000 | $-61,863,000 | $-65,719,000 |
| Interest Expense Non Operating | $117,626,000 | $97,925,000 | $61,863,000 | $65,719,000 |
| Operating Expense | $71,878,000 | $78,739,000 | $81,007,000 | $76,359,000 |
| General And Administrative Expense | $71,878,000 | $78,739,000 | $81,007,000 | $76,359,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-227,212,000 | $-245,761,000 | $-220,074,000 | $-23,926,000 |
| Net Interest Income | $-117,626,000 | $-97,925,000 | $-61,863,000 | $-65,719,000 |
| Normalized Income | $-231,166,000 | $-246,317,000 | $-218,952,000 | $-18,642,000 |
| Net Income From Continuing And Discontinued Operation | $-227,212,000 | $-245,761,000 | $-220,074,000 | $-23,926,000 |
| Total Operating Income As Reported | $-120,475,000 | $-159,549,000 | $-179,427,000 | $25,747,000 |
| Net Income Common Stockholders | $-227,427,000 | $-245,974,000 | $-220,286,000 | $-24,137,000 |
| Net Income | $-227,212,000 | $-245,761,000 | $-220,074,000 | $-23,926,000 |
| Net Income Including Noncontrolling Interests | $-232,271,000 | $-257,437,000 | $-230,656,000 | $-28,724,000 |
| Net Income Continuous Operations | $-232,271,000 | $-257,437,000 | $-230,656,000 | $-28,724,000 |
| Pretax Income | $-232,271,000 | $-257,437,000 | $-230,656,000 | $-28,724,000 |
| Special Income Charges | $3,954,000 | $556,000 | $-1,122,000 | $-5,284,000 |
| Operating Income | $-124,429,000 | $-160,105,000 | $-180,242,000 | $37,228,000 |
| Gross Profit | $-52,551,000 | $-81,366,000 | $-99,235,000 | $113,587,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-10.59 | $-13.75 | $-15.64 | $-2.20 |
| Basic EPS | $-10.59 | $-13.75 | $-15.64 | $-2.20 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-105,256,000 | $-146,480,000 | $-160,725,000 | $49,067,000 |
| Total Unusual Items | $3,954,000 | $556,000 | $-1,122,000 | $-5,284,000 |
| Total Unusual Items Excluding Goodwill | $3,954,000 | $556,000 | $-1,122,000 | $-5,284,000 |
| Reconciled Depreciation | $13,343,000 | $13,588,000 | $6,946,000 | $6,788,000 |
| EBITDA (Bullshit earnings) | $-101,302,000 | $-145,924,000 | $-161,847,000 | $43,783,000 |
| EBIT | $-114,645,000 | $-159,512,000 | $-168,793,000 | $36,995,000 |
| Diluted Average Shares | $21,473,000 | $17,894,000 | $14,087,000 | $11,445,950 |
| Basic Average Shares | $21,473,000 | $17,894,000 | $14,087,000 | $11,445,950 |
| Diluted NI Availto Com Stockholders | $-227,427,000 | $-245,974,000 | $-220,286,000 | $-24,137,000 |
| Preferred Stock Dividends | $215,000 | $213,000 | $212,000 | $211,000 |
| Minority Interests | $5,059,000 | $11,676,000 | $10,582,000 | $4,798,000 |
| Restructuring And Mergern Acquisition | $-3,954,000 | $-556,000 | $-815,000 | $11,481,000 |
| Selling General And Administration | $71,878,000 | $78,739,000 | $81,007,000 | $76,359,000 |
| Other Gand A | $71,878,000 | $78,739,000 | $81,007,000 | $76,359,000 |
| Other Special Charges | - | - | $1,937,000 | $-6,197,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-353,848,000 | $-189,465,000 | $-92,973,000 | $1,076,000 |
| Total Assets | $226,271,000 | $313,913,000 | $413,556,000 | $465,958,000 |
| Total Non Current Assets | $180,697,000 | $201,497,000 | $200,434,000 | $133,984,000 |
| Other Non Current Assets | $5,834,000 | $9,336,000 | $4,453,000 | $9,537,000 |
| Goodwill And Other Intangible Assets | $27,468,000 | $29,134,000 | $31,695,000 | $33,364,000 |
| Other Intangible Assets | $3,376,000 | $4,411,000 | $6,228,000 | $8,488,000 |
| Current Assets | $45,574,000 | $112,416,000 | $213,122,000 | $331,974,000 |
| Other Current Assets | $2,415,000 | $2,372,000 | $3,194,000 | $3,171,000 |
| Prepaid Assets | $2,315,000 | $8,098,000 | $13,829,000 | $20,362,000 |
| Receivables | $407,000 | $25,836,000 | $2,741,000 | $1,518,000 |
| Accounts Receivable | $407,000 | $25,836,000 | $2,741,000 | $1,518,000 |
| Cash Cash Equivalents And Short Term Investments | $40,437,000 | $76,110,000 | $193,358,000 | $306,923,000 |
| Cash And Cash Equivalents | $40,437,000 | $76,110,000 | $178,674,000 | $291,931,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $94,870,000 | $88,469,000 | $78,428,000 | $58,287,000 |
| Long Term Debt And Capital Lease Obligation | $85,024,000 | $75,279,000 | $75,910,000 | $54,932,000 |
| Long Term Debt | $30,473,000 | $12,768,000 | $12,584,000 | $12,823,000 |
| Current Debt And Capital Lease Obligation | $9,846,000 | $13,190,000 | $2,518,000 | $3,355,000 |
| Current Debt | $2,698,000 | $146,000 | $575,000 | $728,000 |
| Other Current Borrowings | $2,552,000 | - | $429,000 | $582,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $532,695,000 | $462,295,000 | $468,458,000 | $418,049,000 |
| Total Non Current Liabilities Net Minority Interest | $311,294,000 | $206,398,000 | $279,506,000 | $261,106,000 |
| Other Non Current Liabilities | $225,127,000 | $129,976,000 | $202,453,000 | $194,974,000 |
| Non Current Deferred Liabilities | $1,143,000 | $1,143,000 | $1,143,000 | $11,200,000 |
| Current Liabilities | $221,401,000 | $255,897,000 | $188,952,000 | $156,943,000 |
| Other Current Liabilities | $121,852,000 | $141,210,000 | $101,486,000 | $75,664,000 |
| Current Deferred Liabilities | $31,000 | $18,000 | $12,269,000 | $12,425,000 |
| Current Notes Payable | $146,000 | $146,000 | $146,000 | $146,000 |
| Payables And Accrued Expenses | $89,672,000 | $101,479,000 | $72,679,000 | $65,499,000 |
| Payables | $61,470,000 | $61,446,000 | $40,939,000 | $30,486,000 |
| Accounts Payable | $61,470,000 | $61,446,000 | $40,939,000 | $30,486,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $-326,380,000 | $-160,331,000 | $-61,278,000 | $34,440,000 |
| Total Equity Gross Minority Interest | $-306,424,000 | $-148,382,000 | $-54,902,000 | $47,909,000 |
| Stockholders Equity | $-326,380,000 | $-160,331,000 | $-61,278,000 | $34,440,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,398,000 | $-955,000 | $915,000 | $1,492,000 |
| Other Equity Adjustments | $-1,398,000 | $-955,000 | $915,000 | $1,492,000 |
| Retained Earnings | $-2,182,880,000 | $-1,955,668,000 | $-1,709,907,000 | $-1,489,833,000 |
| Preferred Securities Outside Stock Equity | - | - | - | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $23,634,670 | $19,718,662 | $15,278,669 | $12,844,895 |
| Share Issued | $23,634,670 | $19,718,662 | $15,278,669 | $12,844,895 |
| Tangible Book Value | $-353,848,000 | $-189,465,000 | $-92,973,000 | $1,076,000 |
| Invested Capital | $-293,209,000 | $-147,417,000 | $-48,119,000 | $47,991,000 |
| Working Capital | $-175,827,000 | $-143,481,000 | $24,170,000 | $175,031,000 |
| Capital Lease Obligations | $61,699,000 | $75,555,000 | $65,269,000 | $44,736,000 |
| Total Capitalization | $-295,907,000 | $-147,563,000 | $-48,694,000 | $47,263,000 |
| Minority Interest | $19,956,000 | $11,949,000 | $6,376,000 | $13,469,000 |
| Additional Paid In Capital | $1,857,662,000 | $1,796,095,000 | $1,644,658,000 | $1,520,212,000 |
| Capital Stock | $236,000 | $197,000 | $3,056,000 | $2,569,000 |
| Common Stock | $236,000 | $197,000 | $3,056,000 | $2,569,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $1,143,000 | $1,143,000 | $1,143,000 | $11,200,000 |
| Long Term Capital Lease Obligation | $54,551,000 | $62,511,000 | $63,326,000 | $42,109,000 |
| Current Deferred Revenue | $31,000 | $18,000 | $12,269,000 | $12,425,000 |
| Current Capital Lease Obligation | $7,148,000 | $13,044,000 | $1,943,000 | $2,627,000 |
| Current Accrued Expenses | $28,202,000 | $40,033,000 | $31,740,000 | $35,013,000 |
| Goodwill | $24,092,000 | $24,723,000 | $25,467,000 | $24,876,000 |
| Net PPE | $147,395,000 | $163,027,000 | $164,286,000 | $91,083,000 |
| Accumulated Depreciation | $-72,553,000 | $-61,943,000 | $-54,075,000 | $-50,539,000 |
| Gross PPE | $219,948,000 | $224,970,000 | $218,361,000 | $141,622,000 |
| Leases | $94,860,000 | $95,645,000 | $28,758,000 | $28,659,000 |
| Construction In Progress | $784,000 | $1,512,000 | $66,464,000 | $16,837,000 |
| Other Properties | $27,308,000 | $29,606,000 | $31,269,000 | $31,054,000 |
| Machinery Furniture Equipment | $78,873,000 | $80,084,000 | $73,930,000 | $41,473,000 |
| Buildings And Improvements | $5,837,000 | $5,837,000 | $5,654,000 | $5,630,000 |
| Land And Improvements | $12,286,000 | $12,286,000 | $12,286,000 | $17,969,000 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Stock | - | $0 | $0 | - |
| Other Short Term Investments | - | $0 | $14,684,000 | $14,992,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-158,891,000 | $-234,156,000 | $-228,435,000 | $-23,669,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-158,315,000 | $-224,202,000 | $-175,373,000 | $10,145,000 |
| Cash Flow From Continuing Operating Activities | $-158,315,000 | $-224,202,000 | $-175,373,000 | $10,145,000 |
| Operating Gains Losses | $-4,589,000 | $-1,964,000 | $-19,802,000 | $-9,498,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-576,000 | $-9,954,000 | $-53,062,000 | $-33,814,000 |
| Investing Cash Flow | $27,000 | $3,400,000 | $-33,610,000 | $-43,150,000 |
| Cash Flow From Continuing Investing Activities | $27,000 | $3,400,000 | $-33,610,000 | $-43,150,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $0 | $-5,172,000 | $-3,789,000 | $-1,654,000 |
| Issuance Of Capital Stock | $38,823,000 | $133,157,000 | $99,211,000 | $220,645,000 |
| Financing Cash Flow | $122,840,000 | $119,866,000 | $95,830,000 | $225,264,000 |
| Cash Flow From Continuing Financing Activities | $122,840,000 | $119,866,000 | $95,830,000 | $225,264,000 |
| Net Other Financing Charges | $73,851,000 | $-606,000 | - | $-1,542,000 |
| Net Common Stock Issuance | $38,823,000 | $127,985,000 | $95,422,000 | $218,991,000 |
| Common Stock Issuance | $38,823,000 | $133,157,000 | $99,211,000 | $220,645,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-10,481,000 | $-8,926,000 | $-490,000 | $-1,317,000 |
| Issuance Of Debt | $20,000,000 | $0 | $0 | $0 |
| Interest Paid Supplemental Data | $2,278,000 | $3,168,000 | $1,143,000 | $1,152,000 |
| End Cash Position | $44,071,000 | $79,779,000 | $181,343,000 | $294,600,000 |
| Beginning Cash Position | $79,779,000 | $181,343,000 | $294,600,000 | $102,505,000 |
| Effect Of Exchange Rate Changes | $-260,000 | $-628,000 | $-104,000 | $-164,000 |
| Changes In Cash | $-35,448,000 | $-100,936,000 | $-113,153,000 | $192,259,000 |
| Proceeds From Stock Option Exercised | $647,000 | $807,000 | $898,000 | $9,132,000 |
| Common Stock Payments | $0 | $-5,172,000 | $-3,789,000 | $-1,654,000 |
| Net Issuance Payments Of Debt | $9,519,000 | $-8,926,000 | $-490,000 | $-1,317,000 |
| Net Long Term Debt Issuance | $9,519,000 | $-8,926,000 | $-490,000 | $-1,317,000 |
| Long Term Debt Payments | $-10,481,000 | $-8,926,000 | $-490,000 | $-1,317,000 |
| Long Term Debt Issuance | $20,000,000 | $0 | $0 | $0 |
| Net Investment Purchase And Sale | $579,000 | $9,991,000 | $371,000 | $-14,992,000 |
| Sale Of Investment | $579,000 | $30,034,000 | $25,000,000 | $0 |
| Purchase Of Investment | $0 | $-20,043,000 | $-24,629,000 | $-14,992,000 |
| Net Business Purchase And Sale | $0 | $0 | $-2,917,000 | $0 |
| Purchase Of Business | $0 | $0 | $-2,917,000 | $0 |
| Net PPE Purchase And Sale | $-552,000 | $-6,591,000 | $-31,064,000 | $-28,158,000 |
| Sale Of PPE | $24,000 | $3,363,000 | $21,998,000 | $5,656,000 |
| Purchase Of PPE | $-576,000 | $-9,954,000 | $-53,062,000 | $-33,814,000 |
| Change In Working Capital | $32,604,000 | $10,756,000 | $24,084,000 | $-9,743,000 |
| Change In Other Working Capital | $-671,000 | $-13,794,000 | $3,569,000 | $-13,982,000 |
| Change In Payables And Accrued Expense | $2,149,000 | $41,979,000 | $8,528,000 | $9,762,000 |
| Change In Accrued Expense | $136,000 | $20,613,000 | $2,034,000 | $-1,062,000 |
| Change In Payable | $2,013,000 | $21,366,000 | $6,494,000 | $10,824,000 |
| Change In Account Payable | $2,013,000 | $21,366,000 | $6,494,000 | $10,824,000 |
| Change In Prepaid Assets | $5,782,000 | $6,032,000 | $11,865,000 | $-5,129,000 |
| Change In Receivables | $25,344,000 | $-23,461,000 | $122,000 | $-394,000 |
| Changes In Account Receivables | $25,344,000 | $-23,461,000 | $122,000 | $-394,000 |
| Other Non Cash Items | $13,235,000 | $-12,014,000 | $19,607,000 | $31,745,000 |
| Stock Based Compensation | $17,390,000 | $22,869,000 | $18,337,000 | $19,577,000 |
| Asset Impairment Charge | $1,973,000 | $0 | $6,111,000 | $0 |
| Depreciation Amortization Depletion | $13,343,000 | $13,588,000 | $6,946,000 | $6,788,000 |
| Depreciation And Amortization | $13,343,000 | $13,588,000 | $6,946,000 | $6,788,000 |
| Gain Loss On Investment Securities | $-3,954,000 | $-556,000 | $-815,000 | - |
| Net Income From Continuing Operations | $-232,271,000 | $-257,437,000 | $-230,656,000 | $-28,724,000 |
| Change In Inventory | - | - | - | $0 |